SCHEMBL2206313

SCHEMBL2206313

CCOC(=O)C1=NOC2(CCC(C(C)(C)C)CC2)C1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.42
KDM4E B2RXH2 5/20 0.42
RECQL P46063 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
HSD17B10 Q99714 2/20 0.40
ALDH1A1 P00352 3/20 0.39
GAA P10253 3/20 0.39
LMNA P02545 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
ALOX12 P18054 1/20 0.39
CYP2C19 P33261 1/20 0.39
ATM Q13315 2/20 0.34
ALOX15 P16050 2/20 0.34
TP53 P04637 1/20 0.34
NPC1 O15118 1/20 0.33
RAB9A P51151 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
GPR119 Q8TDV5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2205084 0.90 MAPT (0.41) MAPTKDM4ERECQLTDP1HSD17B10
SCHEMBL2208839 0.82 ATM (0.39) MAPTHSD17B10ALDH1A1ATMALOX15
SCHEMBL2209410 0.82 ATM (0.39) MAPTHSD17B10ALDH1A1ATMALOX15
SCHEMBL2208836 0.82 ATM (0.39) MAPTHSD17B10ALDH1A1ATMALOX15
SCHEMBL203980 0.82 HSD17B10 (0.46) MAPTKDM4ERECQLTDP1HSD17B10
SCHEMBL2203478 0.82 MAPT (0.45) MAPTKDM4ERECQLTDP1HSD17B10
SCHEMBL4620417 0.81 KDM4E (0.38) MAPTKDM4EALDH1A1GAALMNA
SCHEMBL2310754 0.81 HSD17B10 (0.45) MAPTKDM4ERECQLTDP1HSD17B10
SCHEMBL2358076 0.80 HSD17B10 (0.44) MAPTKDM4ERECQLTDP1HSD17B10
SCHEMBL22057125 0.79 MAPT (0.43) MAPTKDM4ERECQLTDP1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 US disclosed
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 US disclosed
US-7981883-B2 Substituted spiro-compounds and the use thereof for producing medicaments GRUENENTHAL GMBH (DE) 2011-07-19 US disclosed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments GRUENENTHAL GMBH (DE) 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275628-A1 Substituted Spiro-Compounds And The Use Thereof For Producing Medicaments REN, PKD1, PKD2 MAPT 4038/4885KDM4E 3501/4885RECQL 893/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.